- AbbVie will invest $1.4 billion to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, with completion expected by 2028.
- The facility will focus on small-volume parenteral manufacturing and support immunology, neuroscience, and oncology medicines.
AbbVie announced plans to invest $1.4 billion to construct a pharmaceutical manufacturing campus in Durham, North Carolina. The 185-acre site, located near Research Triangle Park, will integrate advanced manufacturing technologies and artificial intelligence to support the production of medicines across immunology, neuroscience, and oncology. Construction is set to begin in 2026, with completion expected by the end of 2028.
The project marks AbbVie’s first major investment in North Carolina and forms part of its broader $100 billion commitment to U.S. research, development, and manufacturing over the next decade. The initial phase will include small volume parenteral (SVP) drug product manufacturing facilities, laboratories, a warehouse, and administrative infrastructure. The site is expected to serve as the company’s U.S. center of excellence for SVP manufacturing.
AbbVie plans to hire 734 employees over the next four years, including engineers, scientists, and manufacturing personnel. The development phase is also expected to generate more than 2,000 construction jobs. The company cited the region’s workforce and expansion potential as factors in selecting Durham for the new facility.
“By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina.”
Robert A. Michael, chairman and chief executive officer of AbbVie
The investment expands AbbVie’s manufacturing footprint in the United States, where the company employs approximately 29,000 people. Over the past 12 months, AbbVie has committed more than $2.2 billion to U.S. manufacturing projects and plans to create over 1,300 jobs across multiple states.
